Catalyst Wire Dossier Catalyst Wire Dossier

Enhertu

trastuzumab deruxtecan · Daiichi Sankyo and AstraZeneca
Drug timelines are a Plus or Pro feature.

95 regulatory and trial events tracked for Enhertu, covering 2019-12-20 to 2026-07-20. Get the full timeline:

Most recent: EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH

See pricing